1. Home
  2. MASS vs ALXO Comparison

MASS vs ALXO Comparison

Compare MASS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MASS
  • ALXO
  • Stock Information
  • Founded
  • MASS 2012
  • ALXO 2015
  • Country
  • MASS United States
  • ALXO United States
  • Employees
  • MASS N/A
  • ALXO N/A
  • Industry
  • MASS Medical/Dental Instruments
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MASS Health Care
  • ALXO Health Care
  • Exchange
  • MASS Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • MASS 77.0M
  • ALXO 76.5M
  • IPO Year
  • MASS 2020
  • ALXO 2020
  • Fundamental
  • Price
  • MASS $2.06
  • ALXO $1.62
  • Analyst Decision
  • MASS Buy
  • ALXO Buy
  • Analyst Count
  • MASS 3
  • ALXO 6
  • Target Price
  • MASS $8.00
  • ALXO $11.00
  • AVG Volume (30 Days)
  • MASS 252.8K
  • ALXO 1.4M
  • Earning Date
  • MASS 11-12-2024
  • ALXO 11-07-2024
  • Dividend Yield
  • MASS N/A
  • ALXO N/A
  • EPS Growth
  • MASS N/A
  • ALXO N/A
  • EPS
  • MASS N/A
  • ALXO N/A
  • Revenue
  • MASS $55,162,000.00
  • ALXO N/A
  • Revenue This Year
  • MASS $15.31
  • ALXO N/A
  • Revenue Next Year
  • MASS $16.10
  • ALXO N/A
  • P/E Ratio
  • MASS N/A
  • ALXO N/A
  • Revenue Growth
  • MASS 16.08
  • ALXO N/A
  • 52 Week Low
  • MASS $1.82
  • ALXO $1.19
  • 52 Week High
  • MASS $12.51
  • ALXO $17.83
  • Technical
  • Relative Strength Index (RSI)
  • MASS 37.83
  • ALXO 52.09
  • Support Level
  • MASS $1.82
  • ALXO $1.47
  • Resistance Level
  • MASS $2.32
  • ALXO $2.05
  • Average True Range (ATR)
  • MASS 0.18
  • ALXO 0.22
  • MACD
  • MASS -0.01
  • ALXO 0.01
  • Stochastic Oscillator
  • MASS 23.08
  • ALXO 33.85

About MASS 908 Devices Inc.

908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: